# Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.

Study · id `cardio:ct-nct02596555` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02596555](<https://clinicaltrials.gov/study/NCT02596555>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02596555

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 400 participants.

## Technical summary

Registry record NCT02596555. Allocation not applicable; no masking; primary purpose treatment. Start 2016-01 (actual); primary completion 2020-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (enrolled count; ClinicalTrials.gov record NCT02596555, source copy `cardio:ctgov-nct02596555-2020-02-17`, retrieved 2026-10-31)
- Started: 2016-01 (actual) (ClinicalTrials.gov record NCT02596555, source copy `cardio:ctgov-nct02596555-2020-02-17`, retrieved 2026-10-31)
- Primary completion: 2020-02 (actual) (ClinicalTrials.gov record NCT02596555, source copy `cardio:ctgov-nct02596555-2020-02-17`, retrieved 2026-10-31)
- Completion: 2020-02 (actual) (ClinicalTrials.gov record NCT02596555, source copy `cardio:ctgov-nct02596555-2020-02-17`, retrieved 2026-10-31)
- Countries: Germany (ClinicalTrials.gov record NCT02596555, source copy `cardio:ctgov-nct02596555-2020-02-17`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02596555-2020-02-17`, retrieved 2026-10-31)

## The registry's words

- Brief title: Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
- Acronym: PEITHO-2
- Condition: Pulmonary Embolism
- Intervention (Drug): Dabigatran
- Lead sponsor: Prof. Stavros Konstantinides, MD
- Lead sponsor class: OTHER
- Collaborator: European Georges Pompidou Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Pulmonary embolism (`cardio:pulmonary-embolism`)
- Registry intervention name matches this record: Dabigatran (`cardio:dabigatran`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial (`cardio:pubmed-34363769`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a978b4476539b52d5e741071db43b0d938e3d537b7d25614681dcd37c51d5782
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
